This document provides information on benign tumours known as polyps, adenomatous polyps, and familial adenomatous polyposis (FAP). It discusses that adenomatous polyps have malignant potential that increases with size, villous type, and dysplasia. FAP is defined by having 100 or more colorectal adenomas and carries a 100% risk of developing colorectal cancer if left untreated. Treatment options for polyps and FAP include polypectomy, colectomy, and proctocolectomy depending on the severity and extent of lesions.
Testicular tumors are rare.
1 – 2 % of all malignant tumors.
Most common malignancy in men in the 15 to 35 year age group.
Benign lesions represent a greater percentage of cases in children than in adults.
Most curable solid neoplasm
The stomach J-shaped. It has two surfaces (the anterior & posterior), two curvatures (the greater & lesser), two orifices (the cardia & pylorus). It has fundus, body and pyloric antrum.
Blood supply
The left gastric artery
Right gastric artery
Right gastro-epiploic artery
Left gastro-epiploic artery
Short gastric arteries
Stomach cancer begins when cancer cells form in the inner lining of your stomach. These cells can grow into a tumor. Also called gastric cancer, the disease usually grows slowly over many years.
It could be:
malignant or benign
primary or secondary
This is a powerpoint slideshow discussing some of the commonest disorders of colon; namely Hirschsprung's disease, Diverticular diseases of colon, ulcerative colitis, pseudomembranous colitis and ischemic colitis.
Please find the power point on Carcinoma of rectum. I tried present it on understandable way and all the contents are reviewed by experts and from very reliable references.
Testicular tumors are rare.
1 – 2 % of all malignant tumors.
Most common malignancy in men in the 15 to 35 year age group.
Benign lesions represent a greater percentage of cases in children than in adults.
Most curable solid neoplasm
The stomach J-shaped. It has two surfaces (the anterior & posterior), two curvatures (the greater & lesser), two orifices (the cardia & pylorus). It has fundus, body and pyloric antrum.
Blood supply
The left gastric artery
Right gastric artery
Right gastro-epiploic artery
Left gastro-epiploic artery
Short gastric arteries
Stomach cancer begins when cancer cells form in the inner lining of your stomach. These cells can grow into a tumor. Also called gastric cancer, the disease usually grows slowly over many years.
It could be:
malignant or benign
primary or secondary
This is a powerpoint slideshow discussing some of the commonest disorders of colon; namely Hirschsprung's disease, Diverticular diseases of colon, ulcerative colitis, pseudomembranous colitis and ischemic colitis.
Please find the power point on Carcinoma of rectum. I tried present it on understandable way and all the contents are reviewed by experts and from very reliable references.
Coloractal Cancer is the most common malignancy of the gastrointestinal system. In this presentation brief information about this cancer is supplied.
may useful for medical students
Colorectal cancer is most common GI cancer
The rectum is the most frequent site involved
Adenoma-carcinoma sequence: Arises from adenoma in stepwise progression
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
2. Benign tumours
‘Polyp’ is a clinical description of any protrusion of the mucosa
They can be single or multiple as part of a polyposis syndrome
Classification of polyps
Inflammatory Hyperplastic Hamartomatous Neoplastic
Ulcerative colitis
Crohn’s colitis
Diverticulitis
Metaplastic Peutz-Jeghers polyp
Juvenile polyp
Adenomatous
•Tubular
•Tubulovillous
•Villous
Adenocarcinoma
Carcinoid tumour
3. Adenomatous polyp
Tubular like a berry on a stalk
Villous ( sessile)
Found on colonoscopic
examination for features of:
Rectal bleeding
Diarrhoea
Mucous discharge
Hypokalaemia
Hypoalbuminaemia
4. Adenomatous polyp
Significance of adenomatous polyps lie in their malignant
potential
The risk of malignancy increases with
Size
< 1cm 1-5% risk
1-2 cms 10% risk
>2 cms 30-50% risk
Villous type
Dysplasia
5. Adenomatous polyp
Treatment
Adenomas larger than 5 mm require polypectomy
Colonoscopic snare polypectomy
Endoscopic mucosal resection (EMR)
Transanal resection
Transanal endoscopic microsurgery (TEMS)
Resection of colon/rectum if massive or extensive
Colonoscopic snare polypectomy(video)
6. Familial adenomatous polyposis(FAP)
FAP is defined clinically by the presence of 100 colorectal
adenomas
Adenomas can also occur in stomach, duodenum or small
intestine
Inherited as an autosomal dominant disease due to mutation of
APC gene located on short arm of 5th chromosome
Occurs in the age group of 15-20 years and in both the sexes
equally
7. Familial adenomatous polyposis(FAP)
Risk of development of colorectal cancer is 100%
Can be associated with duodenal or ampullary carcinoma
Gardner syndrome: desmoid tumours + osteomas +
epidermoid cysts
Turcot’s syndrome: FAP+brain tumours or sarcoma of bone
8. Familial adenomatous polyposis(FAP)
Clinical features
Lower abdominal pain
Loose stools
Weight loss
Blood and mucus in stools
Investigations
Colonoscopy and biopsy
Double contrast barium enema
Screening of all members of the family by genetic testing or by
regular colonoscopy starting at the age of 10-12 years and
repeated every year till the age of 20
If there are no polyps at 20 years, colonoscopy is repeated every
5 years until 50 yrs. Still if there are no polyps there is probably
no inherited gene
9. Familial adenomatous polyposis(FAP)
Treatment
Aim is to prevent the development of colorectal cancer
Surgical options are:
Proctocolectomy with ileal pouch anal anastomosis
Colectomy with ileorectal anastomosis with regular follow up
endoscopic treatment of new rectal polyp
Total proctocolectomy with ileostomy
Ileal ‘J’ pouch anal
anastomosis
Colectomy with ileorectal
anastomosis
Proctocolectomy
with ileostomy
11. Carcinoma colon
More in developed countries
Pathogenesis
Arises from adenomatous polyps after a sequence of genetic
mutations influenced by environmental factors. This is
called adenoma-carcinoma sequence
Possible sequence of adenoma-carcinoma is
Mutation of APC gene –small adenomas- K-ras mutation-larger
adenoma-p53gene mutation- carcinoma
12. Pathogenesis of colonic cancer
Adenoma- carcinoma sequence
80% loss of heterzygosity pathway(APC-K ras-P53)
20% RER pathway(Replication Error Repair) leading to
repeated sequences called microsatellite instability
Colon cancer can be hereditary or non-hereditary
Hereditary
FAP
HNCC
Cronkhite – Canada syndrome
Juvenile polyposis syndrome
Non- hereditary
Sporadic
Familial colonic cancer- in Ashkenazi –Jewish population
13. Types
Synchronous and metachronous
Gross types
Annular
Tubular
Ulcerative
Cauliflower like
Annular
Common on left side
Presents with intestinal obstruction
Ulcerative
Common on right side
Proliferative
Polypoid and is common on right side
15. Staging
Duke’s staging
A: Invasion of but not breaching the muscularis propria
B: Breaching the muscularis propria but not involving
lymph nodes
C: Lymph nodes involved
D: Metastatic disease
16. Staging
TNM Staging
T, Tumour stage
Tis, carcinoma in situ, intraepithelial/invasion into lamina propria
T1, into submucosa
T2, into muscularis propria
T3, into pericolic fat or sub-serosa but not breaching serosa
T4, breaches serosa or directly involving another organ
N, Nodal stage
N0, no nodes involved
N1, 1-3 nodes involved
N2, four or more nodes involved
M, Metastases
M0, no metastasis
M1, metastasis
17. Clinical features
Over 50 years, familial type in younger patients
Anaemia, loss of appetite and weight, abdominal
discomfort and mass per abdomen
20% present with intestinal obstruction
20% present with distant metastasis to liver and other
organs
Right sided growth: Anaemia and mass
Left sided growth: Colicky pain, altered bowel habits,
palpable lump, distention of abdomen. Bladder symptoms
may herald colovesical fistula
Perforation and peritonitis or pericolic abscess may form
24. Adjuvant therapy
Chemotherapy
Indications
Positive node
T4 lesions
Chemotherapy regimes are
5FU+Folinic acid(leucovorin)
Folinic acid (LV)/5 FU/oxaliplatin- FOLFOX
Prognosis
Stage I 90%
Stage II 75%
Stage III 50%
Stage IV less than 5%
Overall 5 year survival is about 50%
25. Rectal cancer
Adenocarcinoma comprise vast majority
Aetiopathogenesis is same as that of colonic cancer
Spread
Local spread
Circumferentially ( 12-18 months)
Muscular coat and parirectal tissue
Prostate, bladder, seminal vesicles
Uterus and vagina
Sacrum and sacral plexus of nerves and ureters
26. Rectal cancer
Spread
Lymphatic
Above peritoneal reflection to lymph nodes along superior
rectal vessels
In mid rectum to pararectal and mid rectal lymph nodes
Blood spread
Liver, lungs and adrenals
Peritoneal spread
27. Clinical features
Bleeding per rectum
Change in bowel habits, tenesmus
Abdominal pain
Back pain(late feature)
Urinary symptoms(invasion of bladder or prostate)
Pelvic pain
Peritonitis due to perforation or jaundice due to liver
metastasis
Examination
Digital rectal examination
28. Investigations
Proctoscopy/ sigmoidoscopy and biopsy
Colonoscopy / barium enema
Usg abdomen
CT scan of abdomen and pelvis for staging
Endorectal ultrasound for staging
PET scan
CEA levels
29. Treatment
Surgery
Principles
Total Mesorectal Excision(TME) to reduce local recurrence
Anterior resection open or laparoscopic
Low anterior resection (open or laparoscopic)
Abdomino-perineal excision (open or laparoscopic)
Hartmann’s resection
For small lesions local excision by
Transanal approach
Transanal endoscopic microsurgery
Palliative sigmoid colostomy for unresectable growth
Adjuvant chemotherapy and radiotherapy